{"id":"rtx-grt7039","safety":{"commonSideEffects":[{"rate":null,"effect":"Taste disturbance"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL17976","moleculeType":"Small molecule","molecularWeight":"628.72"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"P2X3 receptors are ion channels expressed on sensory neurons that mediate pain perception when activated by extracellular ATP. By selectively antagonizing P2X3, RTX-GRT7039 dampens pain signal transmission without affecting other purinergic pathways. This mechanism is particularly relevant for chronic pain conditions where ATP-driven nociception plays a significant role.","oneSentence":"RTX-GRT7039 is a selective antagonist of the P2X3 receptor that reduces pain signaling by blocking ATP-mediated nociceptive transmission.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:32:56.965Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic cough"},{"name":"Neuropathic pain"}]},"trialDetails":[{"nctId":"NCT05248386","phase":"PHASE3","title":"Efficacy and Safety of RTX-GRT7039 in Adult Subjects With Knee Osteoarthritis","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2022-08-26","conditions":"Osteoarthritis","enrollment":469},{"nctId":"NCT05449132","phase":"PHASE3","title":"Comparison of a Single RTX-GRT7039 and Placebo Intra-articular Injection for Pain Associated With Osteoarthritis of the Knee","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2022-09-26","conditions":"Osteoarthritis","enrollment":466},{"nctId":"NCT05377489","phase":"PHASE3","title":"Open-label Trial to Check the Safety and Tolerability of RTX-GRT7039 Injections for Pain Associated With Osteoarthritis of the Knee","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2022-09-15","conditions":"Osteoarthritis","enrollment":714}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"RTX-GRT7039","genericName":"RTX-GRT7039","companyName":"Grünenthal GmbH","companyId":"gr-nenthal-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RTX-GRT7039 is a selective antagonist of the P2X3 receptor that reduces pain signaling by blocking ATP-mediated nociceptive transmission. Used for Chronic cough, Neuropathic pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}